메뉴 건너뛰기




Volumn 31, Issue 3, 2013, Pages 117-126

A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients

Author keywords

Empiric antifungal therapy; Hematological malignancies; Pre emptive antifungal therapy; Stem cell transplant; Targeted antifungal therapy

Indexed keywords

ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

EID: 84887022337     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2031     Document Type: Review
Times cited : (18)

References (54)
  • 1
    • 79951816939 scopus 로고    scopus 로고
    • Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America
    • Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011; 52: e56-e93.
    • (2011) Clin Infect Dis , vol.52
    • Freifeld, A.G.1    Bow, E.J.2    Sepkowitz, K.A.3
  • 2
    • 79955898005 scopus 로고    scopus 로고
    • Third European Conference on Infections in Leukemia European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update
    • Maertens J, Marchetti O, Herbrecht R, et al. Third European Conference on Infections in Leukemia European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant 2011; 46: 709-718.
    • (2011) Bone Marrow Transplant , vol.46 , pp. 709-718
    • Maertens, J.1    Marchetti, O.2    Herbrecht, R.3
  • 3
    • 0028188233 scopus 로고
    • The Delphi technique: a methodological discussion
    • William PL, Webb C. The Delphi technique: a methodological discussion. J Adv Nurs 1994; 19: 180-186.
    • (1994) J Adv Nurs , vol.19 , pp. 180-186
    • William, P.L.1    Webb, C.2
  • 4
    • 85081456536 scopus 로고
    • Group techniques for program planning: a guide to nominal group and Delphi processes. Scott, Foresman and Co Glenview, IL, USA
    • Delbecq AL, van de Ven AH, Gustafson DH. Group techniques for program planning: a guide to nominal group and Delphi processes. Scott, Foresman and Co Glenview, IL, USA, 1975.
    • (1975)
    • Delbecq, A.L.1    van de Ven, A.H.2    Gustafson, D.H.3
  • 5
    • 0019946004 scopus 로고
    • Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
    • Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-111.
    • (1982) Am J Med , vol.72 , pp. 101-111
    • Pizzo, P.A.1    Robichaud, K.J.2    Gill, F.A.3    Witebsky, F.G.4
  • 6
    • 0024371959 scopus 로고
    • Empiric antifungal therapy in febrile granulocytopenic patients
    • EORTC International Antimicrobial Therapy Cooperative Group.
    • EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668-672.
    • (1989) Am J Med , vol.86 , pp. 668-672
  • 7
    • 0032442010 scopus 로고    scopus 로고
    • A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia
    • Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998; 105: 478-483.
    • (1998) Am J Med , vol.105 , pp. 478-483
    • Malik, I.A.1    Moid, I.2    Aziz, Z.3    Khan, S.4    Suleman, M.5
  • 8
    • 7344264567 scopus 로고    scopus 로고
    • Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
    • White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296-302.
    • (1998) Clin Infect Dis , vol.27 , pp. 296-302
    • White, M.H.1    Bowden, R.A.2    Sandler, E.S.3
  • 9
    • 0033545538 scopus 로고    scopus 로고
    • Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
    • Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-771.
    • (1999) N Engl J Med , vol.340 , pp. 764-771
    • Walsh, T.J.1    Finberg, R.W.2    Arndt, C.3
  • 10
    • 0037165259 scopus 로고    scopus 로고
    • Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
    • Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2001; 346: 225-234.
    • (2001) N Engl J Med , vol.346 , pp. 225-234
    • Walsh, T.J.1    Pappas, P.2    Winston, D.J.3
  • 11
    • 4644346490 scopus 로고    scopus 로고
    • Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia
    • Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
    • (2004) N Engl J Med , vol.351 , pp. 1391-1402
    • Walsh, T.J.1    Teppler, H.2    Donowitz, G.R.3
  • 12
    • 0033972985 scopus 로고    scopus 로고
    • A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer
    • Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108: 282-289.
    • (2000) Am J Med , vol.108 , pp. 282-289
    • Winston, D.J.1    Hathorn, J.W.2    Schuster, M.G.3    Schiller, G.J.4    Territo, M.C.5
  • 13
    • 0034456963 scopus 로고    scopus 로고
    • A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
    • Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31: 1155-1163.
    • (2000) Clin Infect Dis , vol.31 , pp. 1155-1163
    • Wingard, J.R.1    White, M.H.2    Anaissie, E.3
  • 14
    • 0035909054 scopus 로고    scopus 로고
    • Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial
    • Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001; 135: 412-422.
    • (2001) Ann Intern Med , vol.135 , pp. 412-422
    • Boogaerts, M.1    Winston, D.J.2    Bow, E.J.3
  • 15
    • 77951874577 scopus 로고    scopus 로고
    • A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia
    • Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29: 415-420.
    • (2010) Pediatr Infect Dis J , vol.29 , pp. 415-420
    • Maertens, J.A.1    Madero, L.2    Reilly, A.F.3
  • 16
    • 43049116174 scopus 로고    scopus 로고
    • Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management
    • Penack O, Rempf P, Graf B, Blau IW, Thiel E. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann Oncol 2008; 19: 984-989.
    • (2008) Ann Oncol , vol.19 , pp. 984-989
    • Penack, O.1    Rempf, P.2    Graf, B.3    Blau, I.W.4    Thiel, E.5
  • 17
    • 73949145147 scopus 로고    scopus 로고
    • Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients
    • Armenian SH, Nash KA, Kapoor N, et al. Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. J Pediatr Hematol Oncol 2009; 31: 920-926.
    • (2009) J Pediatr Hematol Oncol , vol.31 , pp. 920-926
    • Armenian, S.H.1    Nash, K.A.2    Kapoor, N.3
  • 18
    • 58349122651 scopus 로고    scopus 로고
    • Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients
    • Barnes RA, White PL, Bygrave C, Evans N, Healy B, Kell J. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 2009; 62: 64-69.
    • (2009) J Clin Pathol , vol.62 , pp. 64-69
    • Barnes, R.A.1    White, P.L.2    Bygrave, C.3    Evans, N.4    Healy, B.5    Kell, J.6
  • 19
    • 0035889460 scopus 로고    scopus 로고
    • Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer
    • Lin MT, Lu HC, Chen WL. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis 2001; 33: 1621-1627.
    • (2001) Clin Infect Dis , vol.33 , pp. 1621-1627
    • Lin, M.T.1    Lu, H.C.2    Chen, W.L.3
  • 20
    • 27444447144 scopus 로고    scopus 로고
    • Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study
    • Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-1250.
    • (2005) Clin Infect Dis , vol.41 , pp. 1242-1250
    • Maertens, J.1    Theunissen, K.2    Verhoef, G.3
  • 21
    • 34547841536 scopus 로고    scopus 로고
    • Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients
    • Oshima K, Kanda Y, Asano-Mori Y, et al. Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 2007; 60: 350-355.
    • (2007) J Antimicrob Chemother , vol.60 , pp. 350-355
    • Oshima, K.1    Kanda, Y.2    Asano-Mori, Y.3
  • 22
    • 67651174360 scopus 로고    scopus 로고
    • An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality
    • Dignan FL, Evans SO, Ethell ME, et al. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant 2009; 44: 51-56.
    • (2009) Bone Marrow Transplant , vol.44 , pp. 51-56
    • Dignan, F.L.1    Evans, S.O.2    Ethell, M.E.3
  • 23
    • 77449124531 scopus 로고    scopus 로고
    • Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study
    • Girmenia C, Micozzi A, Gentile G, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010; 28: 667-674.
    • (2010) J Clin Oncol , vol.28 , pp. 667-674
    • Girmenia, C.1    Micozzi, A.2    Gentile, G.3
  • 24
    • 75149154262 scopus 로고    scopus 로고
    • Empirical antifungal therapy in selected patients with persistent febrile neutropenia
    • Aguilar-Guisado M, Espigado I, Cordero E, et al. Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow Transplant 2010; 45: 159-164.
    • (2010) Bone Marrow Transplant , vol.45 , pp. 159-164
    • Aguilar-Guisado, M.1    Espigado, I.2    Cordero, E.3
  • 25
    • 63649156819 scopus 로고    scopus 로고
    • Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial
    • Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042-1051.
    • (2009) Clin Infect Dis , vol.48 , pp. 1042-1051
    • Cordonnier, C.1    Pautas, C.2    Maury, S.3
  • 26
    • 64949149897 scopus 로고    scopus 로고
    • A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT
    • Hebart H, Klingspor L, Klingebiel T, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 2009; 43(7): 553-561.
    • (2009) Bone Marrow Transplant , vol.43 , Issue.7 , pp. 553-561
    • Hebart, H.1    Klingspor, L.2    Klingebiel, T.3
  • 27
    • 78650210760 scopus 로고    scopus 로고
    • Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT
    • Blennow O, Remberger M, Klingspor L, et al. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant 2010; 45: 1710-1718.
    • (2010) Bone Marrow Transplant , vol.45 , pp. 1710-1718
    • Blennow, O.1    Remberger, M.2    Klingspor, L.3
  • 28
    • 79954583323 scopus 로고    scopus 로고
    • Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study
    • Tan BH, Low JG, Chlebicka NL, et al. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. Int J Infect Dis 2011; 15: e350-e356.
    • (2011) Int J Infect Dis , vol.15
    • Tan, B.H.1    Low, J.G.2    Chlebicka, N.L.3
  • 29
    • 0037043655 scopus 로고    scopus 로고
    • Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
    • Herbrecht R, Denning DW, Patterson TF, et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
    • (2002) N Engl J Med , vol.347 , pp. 408-415
    • Herbrecht, R.1    Denning, D.W.2    Patterson, T.F.3
  • 30
    • 34248160575 scopus 로고    scopus 로고
    • Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)
    • Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-1297.
    • (2007) Clin Infect Dis , vol.44 , pp. 1289-1297
    • Cornely, O.A.1    Maertens, J.2    Bresnik, M.3
  • 31
    • 76249115229 scopus 로고    scopus 로고
    • An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients
    • Viscoli C, Herbrecht R, Akan H, et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64: 1274-1281.
    • (2009) J Antimicrob Chemother , vol.64 , pp. 1274-1281
    • Viscoli, C.1    Herbrecht, R.2    Akan, H.3
  • 32
    • 77955012411 scopus 로고    scopus 로고
    • Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
    • Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45: 1227-1233.
    • (2010) Bone Marrow Transplant , vol.45 , pp. 1227-1233
    • Herbrecht, R.1    Maertens, J.2    Baila, L.3
  • 33
    • 0036133373 scopus 로고    scopus 로고
    • Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus
    • Ascioglu S, Rex JH, de Pauw B, et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
    • (2002) Clin Infect Dis , vol.34 , pp. 7-14
    • Ascioglu, S.1    Rex, J.H.2    de Pauw, B.3
  • 34
    • 80052795068 scopus 로고    scopus 로고
    • Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease
    • Cornely OA, Maertens J, Bresnik M, et al. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 2011; 54: e449-e455.
    • (2011) Mycoses , vol.54
    • Cornely, O.A.1    Maertens, J.2    Bresnik, M.3
  • 35
    • 46249126149 scopus 로고    scopus 로고
    • Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
    • De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
    • (2008) Clin Infect Dis , vol.46 , pp. 1813-1821
    • De Pauw, B.1    Walsh, T.J.2    Donnelly, J.P.3
  • 36
    • 24144483474 scopus 로고    scopus 로고
    • Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality
    • Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645.
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 3640-3645
    • Morrell, M.1    Fraser, V.J.2    Kollef, M.H.3
  • 38
    • 48749096676 scopus 로고    scopus 로고
    • Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis
    • Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-509.
    • (2008) Clin Infect Dis , vol.47 , pp. 503-509
    • Chamilos, G.1    Lewis, R.E.2    Kontoyiannis, D.P.3
  • 39
    • 82455220443 scopus 로고    scopus 로고
    • Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay
    • Torelli R, Sanguinetti M, Moody A, et al. Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol 2011; 49: 4273-4278.
    • (2011) J Clin Microbiol , vol.49 , pp. 4273-4278
    • Torelli, R.1    Sanguinetti, M.2    Moody, A.3
  • 40
    • 79958702180 scopus 로고    scopus 로고
    • Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients
    • Nguyen MH, Leather H, Clancy CJ, et al. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant 2011; 17: 1043-1050.
    • (2011) Biol Blood Marrow Transplant , vol.17 , pp. 1043-1050
    • Nguyen, M.H.1    Leather, H.2    Clancy, C.J.3
  • 41
    • 84863835368 scopus 로고    scopus 로고
    • Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples
    • Reinwald M, Spiess B, Heinz WJ, et al. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol 2012; 89: 120-127.
    • (2012) Eur J Haematol , vol.89 , pp. 120-127
    • Reinwald, M.1    Spiess, B.2    Heinz, W.J.3
  • 42
    • 33745797267 scopus 로고    scopus 로고
    • Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients
    • Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006; 162: 1-15.
    • (2006) Mycopathologia , vol.162 , pp. 1-15
    • Bhatti, Z.1    Shaukat, A.2    Almyroudis, N.G.3    Segal, B.H.4
  • 43
    • 20144389929 scopus 로고    scopus 로고
    • Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature
    • Girmenia C, Pagano L, Martino B, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005; 43: 1818-1828.
    • (2005) J Clin Microbiol , vol.43 , pp. 1818-1828
    • Girmenia, C.1    Pagano, L.2    Martino, B.3
  • 44
    • 0035889586 scopus 로고    scopus 로고
    • Risk factors for Candida tropicalis fungemia in patients with cancer
    • Kontoyiannis DP, Vaziri I, Hanna HA, et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001; 33: 1676-1681.
    • (2001) Clin Infect Dis , vol.33 , pp. 1676-1681
    • Kontoyiannis, D.P.1    Vaziri, I.2    Hanna, H.A.3
  • 45
    • 33747616462 scopus 로고    scopus 로고
    • Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey
    • Cornillet A, Camus C, Nimubona S. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43: 577-584.
    • (2006) Clin Infect Dis , vol.43 , pp. 577-584
    • Cornillet, A.1    Camus, C.2    Nimubona, S.3
  • 46
    • 1442277074 scopus 로고    scopus 로고
    • Neutropenic enterocolitis in acute leukemia: diagnostic and therapeutic dilemma
    • Capria S, Vitolo D, Cartoni C, et al. Neutropenic enterocolitis in acute leukemia: diagnostic and therapeutic dilemma. Ann Hematol 2004; 83: 195-197.
    • (2004) Ann Hematol , vol.83 , pp. 195-197
    • Capria, S.1    Vitolo, D.2    Cartoni, C.3
  • 47
    • 34547232300 scopus 로고    scopus 로고
    • CNS aspergillosis: recognition, diagnosis and management
    • Ruhnke M, Kofla G, Otto K, Schwartz S. CNS aspergillosis: recognition, diagnosis and management. CNS Drugs 2007; 21: 659-676.
    • (2007) CNS Drugs , vol.21 , pp. 659-676
    • Ruhnke, M.1    Kofla, G.2    Otto, K.3    Schwartz, S.4
  • 48
    • 20444371963 scopus 로고    scopus 로고
    • Antifungal therapy decreases sensitivity of the Aspergillus galactomannanenzyme immunoassay
    • Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannanenzyme immunoassay. Clin Infect Dis 2005; 40: 1762-1769.
    • (2005) Clin Infect Dis , vol.40 , pp. 1762-1769
    • Marr, K.A.1    Laverdiere, M.2    Gugel, A.3    Leisenring, W.4
  • 49
    • 33846462456 scopus 로고    scopus 로고
    • Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
    • Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-359.
    • (2007) N Engl J Med , vol.356 , pp. 348-359
    • Cornely, O.A.1    Maertens, J.2    Winston, D.J.3
  • 50
    • 33846410666 scopus 로고    scopus 로고
    • Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease
    • Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
    • (2007) N Engl J Med , vol.356 , pp. 335-347
    • Ullmann, A.J.1    Lipton, J.H.2    Vesole, D.H.3
  • 51
    • 77954187715 scopus 로고    scopus 로고
    • Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort
    • Vehreschild JJ, Rüping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010; 65: 1466-1471.
    • (2010) J Antimicrob Chemother , vol.65 , pp. 1466-1471
    • Vehreschild, J.J.1    Rüping, M.J.2    Wisplinghoff, H.3
  • 52
    • 84859476239 scopus 로고    scopus 로고
    • Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single center real life experience
    • Girmenia C, Frustaci AM, Gentile G, et al. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single center real life experience. Haematologica 2012; 97: 560-567.
    • (2012) Haematologica , vol.97 , pp. 560-567
    • Girmenia, C.1    Frustaci, A.M.2    Gentile, G.3
  • 53
    • 39449117139 scopus 로고    scopus 로고
    • Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
    • Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211.
    • (2008) Clin Infect Dis , vol.46 , pp. 201-211
    • Pascual, A.1    Calandra, T.2    Bolay, S.3    Buclin, T.4    Bille, J.5    Marchetti, O.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.